NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 105,000 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the transaction, the chief accounting officer directly owned 24,353 shares of the company's stock, valued at $738,870.02. This trade represents a 81.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Louise Frederika Kooij also recently made the following trade(s):
- On Monday, June 22nd, Louise Frederika Kooij sold 40,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $30.20, for a total value of $1,208,000.00.
- On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00.
NewAmsterdam Pharma Trading Down 7.4%
NASDAQ:NAMS opened at $27.98 on Wednesday. The business's 50-day moving average is $32.61 and its 200 day moving average is $32.78. NewAmsterdam Pharma Company N.V. has a 12 month low of $21.14 and a 12 month high of $42.21. The company has a market capitalization of $3.27 billion, a P/E ratio of -15.63 and a beta of 0.08.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The firm had revenue of $3.04 million for the quarter. On average, research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on NAMS shares. Jefferies Financial Group reissued a "buy" rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Royal Bank Of Canada upped their price target on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an "outperform" rating in a research note on Tuesday, June 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an "outperform" rating and a $58.00 price objective for the company. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $49.42.
View Our Latest Stock Report on NAMS
Institutional Investors Weigh In On NewAmsterdam Pharma
Institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC boosted its holdings in shares of NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company's stock worth $25,000 after purchasing an additional 708 shares during the period. Wells Fargo & Company MN increased its position in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company's stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. KBC Group NV purchased a new stake in NewAmsterdam Pharma during the 1st quarter valued at $37,000. Navalign LLC purchased a new stake in NewAmsterdam Pharma during the 4th quarter valued at $46,000. Finally, Empowered Funds LLC bought a new stake in NewAmsterdam Pharma in the fourth quarter worth $85,000. 89.89% of the stock is owned by institutional investors.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
